Skip to main content
SpringerLink
Log in

Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Introduction

Thiopurines (azathioprine and 6-mercaptopurine) have been used in the management of UC patients for over three decades. Nearly half of patients with UC treated with thiopurines fail to achieve remission or lose remission during treatment. Factors associated with thiopurine failure are poorly understood. The primary aim of our study was to investigate patient-related factors which are associated with thiopurine failure.

Methods

TNF-alpha antagonist-naïve patients with histological diagnosis of UC, receiving thiopurine therapy, with follow-up data from 1 to 3 years were included in the study. Data regarding demographics, laboratory results, and disease characteristics were collected. The primary endpoint was failure of thiopurine therapy, defined as treatment with steroids, therapeutic escalation to TNF-alpha antagonist therapy, or need for surgery.

Results

Of the 563 patients identified using ICD-9 codes, 78 TNF-alpha antagonist-naïve patients with a histological diagnosis of UC, receiving thiopurine treatment, were identified. Over the three-year follow-up period, 38 patients failed thiopurine treatment. On adjusted Cox regression, BMI < 25 kg/m2 (HR 3, 95 % CI 1.55–5.83; p value = 0.001) was significantly associated with thiopurine failure. Furthermore, although not statistically significant, there was a strong trend toward thiopurine failure among patients with serum albumin level < 4 g/dL (HR 1.98, 95 % CI 0.97–4; p value = 0.06), non-smoking status (HR 2.2, 95 % CI 0.96–5.06; p value = 0.06), and higher degree of colon inflammation (HR 1.49, 95 % CI 0.96–2.32; p value = 0.08).

Discussion

Our results show that low body mass index is associated with increased risk of failure of thiopurine treatment. Furthermore, there was a strong trend toward thiopurine failure among patients with low serum albumin level (<4gm/dL). These factors should be considered as markers of non-response to thiopurine monotherapy for patients with moderately severe ulcerative colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725. doi:10.1056/NEJMra1102942.

    Article  PubMed  CAS  Google Scholar 

  2. Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. Gut. 2014;. doi:10.1136/gutjnl-2013-306711.

    Google Scholar 

  3. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485–489.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20–22.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Cañas-Ventura A, Márquez L, Ricart E, et al. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis. 2014;8:1287–1293. doi:10.1016/j.crohns.2014.03.014.

    Article  PubMed  Google Scholar 

  6. Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126–137. doi:10.1111/j.1365-2036.2009.04023.x.

    Article  PubMed  CAS  Google Scholar 

  7. Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev Gastroenterol Hepatol. 2008;2:23–34. doi:10.1586/17474124.2.1.23.

    Article  PubMed  CAS  Google Scholar 

  8. Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575–588. doi:10.1586/egh.10.59.

    Article  PubMed  CAS  Google Scholar 

  9. Chatu S, Saxena S, Subramanian V, et al. The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn’s disease: national UK population-based study 1989–2010. Am J Gastroenterol. 2014;109:409–416. doi:10.1038/ajg.2013.462.

    Article  PubMed  CAS  Google Scholar 

  10. Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion. 2000;62:249–254. doi:10.1159/000007823.

    Article  PubMed  CAS  Google Scholar 

  11. Saibeni S, Virgilio T, D’Incà R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis. 2008;40:814–820. doi:10.1016/j.dld.2008.03.016.

    Article  PubMed  CAS  Google Scholar 

  12. National Health Accounts Historical 2014. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html. Accessed December 16, 2014.

  13. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57:3080–3091. doi:10.1007/s10620-012-2289-y.

    Article  PubMed  Google Scholar 

  14. D’Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010;7:86–92. doi:10.1038/nrgastro.2009.222.

    Article  PubMed  Google Scholar 

  15. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603–1609. doi:10.1002/ibd.21488.

    Article  PubMed  CAS  Google Scholar 

  16. Hanson K, Benouna SME. Managing the costs of your IBD care 2013. http://www.ccfa.org/assets/pdfs/managing-costs-of-ibd.pdf. Accessed December 17, 2014.

  17. Sochacka J, Baran W. The investigation of the binding of 6-mercaptopurine to site I on human serum albumin. Protein J. 2012;31:689–702. doi:10.1007/s10930-012-9449-y.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Tesseromatis C, Alevizou A. The role of the protein-binding on the mode of drug action as well the interactions with other drugs. Eur J Drug Metab Pharmacokinet. 2008;33:225–230.

    Article  PubMed  CAS  Google Scholar 

  19. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247–2259. doi:10.1097/MIB.0000000000000212.

    Article  PubMed  Google Scholar 

  20. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211–1228. doi:10.1007/s00228-009-0718-4.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297–308.

    Article  PubMed  CAS  Google Scholar 

  22. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375–378.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Kelley-Quon LI, Jen HC, Ziring DA, et al. Predictors of proctocolectomy in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2012;55:534–540. doi:10.1097/MPG.0b013e3182619d26.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Stabroth-Akil D, Leifeld L, Pfützer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2014. doi:10.1007/s00384-014-2051-3.

    PubMed  Google Scholar 

  25. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn’s disease clinical course and severity in obese patients. Clin Nutr. 2002;21:51–57. doi:10.1054/clnu.2001.0503.

    Article  PubMed  CAS  Google Scholar 

  26. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:482–488. doi:10.1016/j.cgh.2005.12.015.

    Article  PubMed  Google Scholar 

  27. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407. doi:10.1038/ncpgasthep0528.

    Article  PubMed  CAS  Google Scholar 

  28. Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn’s disease. Gut. 2013;62:852–862. doi:10.1136/gutjnl-2011-301424.

    Article  PubMed  CAS  Google Scholar 

  29. Yamamoto K, Kiyohara T, Murayama Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn’s disease. Gut. 2005;54:789–796. doi:10.1136/gut.2004.046516.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Iskandar H, Greer JB, Schraut WH, et al. IBD LIVE case series-case 1: smoking, a controversial but effective treatment for ulcerative colitis. Inflamm Bowel Dis. 2014;20:1696–1701. doi:10.1097/MIB.0000000000000188.

    Article  PubMed  Google Scholar 

  31. Aldhous MC, Drummond HE, Anderson N, et al. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol. 2007;102:589–597. doi:10.1111/j.1572-0241.2007.01065.x.

    Article  PubMed  Google Scholar 

  32. Tobin MV, Logan RF, Langman MJ, McConnell RB, Gilmore IT. Cigarette smoking and inflammatory bowel disease. Gastroenterology. 1987;93:316–321.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Henry Ford Hospital, Madison Heights, MI, USA

    Sudeep Dhoj Thapa, Hiba Hadid, Mohammed Usman, Waseem Imam, Ahmad Hassan, Jason Schairer, Syed-Mohammed R. Jafri & Nirmal Kaur

Authors
  1. Sudeep Dhoj Thapa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiba Hadid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammed Usman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Waseem Imam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmad Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jason Schairer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Syed-Mohammed R. Jafri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nirmal Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sudeep Dhoj Thapa.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thapa, S.D., Hadid, H., Usman, M. et al. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients. Dig Dis Sci 61, 230–237 (2016). https://doi.org/10.1007/s10620-015-3864-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3864-9

Keywords

Search

Navigation